Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 14, Number 10—October 2008
Research

Prophylaxis after Exposure to Coxiella burnetii

Claire E. MoodieComments to Author , Herbert A. Thompson, Martin I. Meltzer, and David L. Swerdlow
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA;

Main Article

Figure 4

Cases of illness averted in the general population after Coxiella burnetii exposure with the use of postexposure prophylaxis while accounting for a 1.0% probability of adverse events, broken down by virulence scenario and drug efficacy. The “best estimate” scenario (primary analysis, A) uses best estimate input values, the “less virulent” scenario (B) uses input values that result in the least harmful outcome, the “more virulent” scenario (C) applies input values that result in the most harmful

Figure 4. Cases of illness averted in the general population after Coxiella burnetii exposure with the use of postexposure prophylaxis while accounting for a 1.0% probability of adverse events, broken down by virulence scenario and drug efficacy. The “best estimate” scenario (primary analysis, A) uses best estimate input values, the “less virulent” scenario (B) uses input values that result in the least harmful outcome, the “more virulent” scenario (C) applies input values that result in the most harmful outcome or worst-case scenario. Drug efficacy refers to the efficacy of doxycycline as a post-exposure prophylaxis against C. burnetii infection. Analyses for doxycycline (used by the general and high-risk populations) were run at 2 potential drug efficacies: 96.5% and 82%. The threshold points, the probability of exposure where the risk of adverse events equals the risk of illness, are noted on the graphs.

Main Article

Page created: July 13, 2010
Page updated: July 13, 2010
Page reviewed: July 13, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external